Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients

The Tohoku Journal of Experimental Medicine
Esmen BaltaliGulten Tekuzman

Abstract

Single-agent paclitaxel has been shown to be effective as both first- and second-line treatment of metastatic breast cancer, and the efficacy and tolerability of weekly administration of paclitaxel has generated much interest. Fifty-two patients with pretreated metastatic breast cancer who were admitted to Hacettepe University between January 2001 and June 2002 were retrospectively analyzed in this study. Paclitaxel was administered weekly in a dose of 80 mg/m(2) over 1 hour. The median number of cycles delivered was 20 weeks (range, 8 to 24). The median delivered dose was 2400 mg (range, 960 to 3840 mg). At a median follow-up of 12.3 months (range, 6 to 17), all patients were assessable for response and toxicity. A complete response and partial response were observed in 7 (13.5%), and 19 (36.5%) patients, respectively. Overall response rate was 50%. Median duration of response was 10 months (range, 3 to 16). Therapy was generally well tolerated, and toxicities were manageable. Severe leukopenia was seen in two (4%) patients. Based on these results, we conclude that weekly paclitaxel is a well-tolerated and highly effective regimen in pre-treated metastatic breast cancer.

References

Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzB Winograd
Sep 18, 1996·Journal of the National Cancer Institute·C G MilrossL Milas
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanL Norton
Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FossatiA Liberati
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J F BishopR Canetta
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A PerezR Patel
Dec 31, 2002·Critical Reviews in Oncology/hematology·Hans-Joachim Lück, Henri Roché
Jan 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A J ten TijeJ Verweij
Apr 8, 2004·Acta Oncologica·Erik Andreas WistKnut Fjaestad

❮ Previous
Next ❯

Citations

Dec 1, 2012·Physical Biology·David LiaoThea D Tlsty
Dec 30, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J TruongK K W Chan
Mar 19, 2008·Molecular Cancer Therapeutics·Vessela VassilevaMicheline Piquette-Miller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Critical Reviews in Oncology/hematology
Paolo MarchettiCorrado Ficorella
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Alphonse G TaghianSimon N Powell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S E JonesP M Ravdin
© 2022 Meta ULC. All rights reserved